Trials / Unknown
UnknownNCT01804920
D-Serine Treatment For Tardive Dyskinesia
D-SERINE TREATMENT FOR TARDIVE DYSKINESIA
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Herzog Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the glutamatergic NMDA receptor. Previous studies have suggested that D-serine may improve motor symptoms, including dyskinesias, which are caused by treatment with presently used antipsychotics drugs. The hypothesis under investigation in the present study is that D-serine adjuvant treatment may improve TD in schizophrenia patients diagnosed with this disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | D-serine | |
| DIETARY_SUPPLEMENT | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2013-03-05
- Last updated
- 2018-10-11
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01804920. Inclusion in this directory is not an endorsement.